Shalby Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Shalby Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offering of 20,354,838 equity shares of face value of Rs. 10 each ("equity shares") of Shalby Limited ("company" or "issuer") for cash at a price of Rs. 248 per equity share (including a share premium of Rs. 238 per equity share) aggregating up to Rs. 504.80 crores ("offer") comprising a fresh issue of 19,354,838 equity shares aggregating up to Rs. 480.00 crores ("fresh issue") and an offer for sale of 1,000,000 equity shares by Dr. Vikram Shah (the "selling shareholder") aggregating up to Rs. 24.80 crores ("offer for sale"). The offer comprises a net offer to the public of up to 20,233,838 equity shares (the "net offer") and a reservation of 121,000 equity shares aggregating up to Rs. 3.00 crores for subscription by eligible employees (the "employee reservation portion"). The offer will constitute 18.85% of the post-offer paid-up equity share capital and the net offer will constitute 18.73% of the post-offer paid-up equity share capital. The Face value of the equity shares is Rs. 10 each. The Offer price is Rs. 248 per equity share and is 24.80 times the face value of the equity shares
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- A significant portion of Company's revenue is currently generated from two hospitals SG Shalby and Krishna Shalby. Further, a majority of its hospitals are located in the state of Gujarat. Any material impact on the revenue from these hospitals will impact its business, prospects, financial condition and results of operations significantly.
- Company is dependent on one field of specialty for a substantial portion of its revenue, i.e. orthopaedics. Any material impact on its earnings from orthopaedics will impact its financial condition and results of operations significantly.
- Company's O&M partner, SMJH Trust, has not perfected its leasehold rights upon the land on which Shalby Jabalpur has been constructed. Accordingly, its rights arising out of its O&M arrangement with SMJH Trust in respect of Shalby Jabalpur may be impaired, thus adversely affecting its revenue, profits, and financial conditions.
- Company have not executed definitive agreements in respect of some of its Outpatient Clinics with third parties. Further, Zynova Shalby is presently being operated under a memorandum of understanding, and a detailed agreement is proposed to be executed upon completion of 36 months from the date of commencement of its management and operation of Zynova Shalby.
- Company's revenue is primarily dependent on inpatient treatments, which could decline due to a variety of factors. Any such decline will adversely affect its financial condition and results of operations.